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Abstract
Purpose—Early and accurate diagnosis of Bladder cancer (BCa) will contribute extensively to 
the management of the disease. The purpose of this review was to briefly describe the conventional 
imaging methods and other novel imaging modalities used for early detection of BCa and outline 
their pros and cons.
Methods—Literature search was performed on Pubmed, PMC, and Google scholar for the period 
of January 2014 to February 2018 and using such words as “bladder cancer, bladder tumor, 
bladder cancer detection, diagnosis and imaging”.
Results—A total of 81 published papers were retrieved and are included in the review. For 
patients with hematuria and suspected of BCa, cystoscopy and CT are most commonly 
recommended. Ultrasonography, MRI, PET/CT using 18F-FDG or 11C-choline and recently 
PET/MRI using 18F-FDG also play a prominent role in detection of BCa.
Conclusion—For initial diagnosis of BCa, cystoscopy is generally performed. However, 
cystoscopy can not accurately detect carcinoma insitu (CIS) and can not distinguish benign masses 
from malignant lesions. CT is used in two modes, CT and computed tomographic urography 
(CTU), both for dignosis and staging of BCa. However, they cannot differentiate T1 and T2 BCa. 
MRI is performed to diagnose invasive BCa and can differentiate muscle invasive bladder 
carcinoma (MIBC) from non-muscle invasive bladder carcinoma (NMIBC). However, CT and 
MRI have low sensitivity for nodal staging. For nodal staging PET/CT is preferred. PET/MRI 
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provides better differentiation of normal and pathologic structures as compared with PET/CT. 
Nonetheless none of the approaches can address all issues related for the management of BCa. 
Novel imaging methods that target specific biomarkers, image BCa early and accurately, and stage 
the disease are warranted.
Keywords
Bladder Cancer; Imaging; Cancer Diagnosis; CT; MRI; PET/CT
Introduction
Bladder cancer (BCa) presents as the second most common genitourinary malignancy [1–3]. 
Early and accurate diagnosis can reduce mortality [4]. A typical symptom of BCa is painless 
hematuria [5]. For initial diagnosis, urine analyses are commonly performed. Imaging plays 
an important role in assessing the extent of BCa for which computed tomography (CT), 
ultrasonography (US), magnetic resonance imaging (MRI) and molecular imaging 
modalities such as positron emission tomography/computed tomography (PET/CT), or 
positron emission tomography/magnetic resonance imaging (PET/MRI) are used [6, 7]. The 
purpose of this review was to briefly describe the conventional imaging methods, and new 
imaging modalities used for imaging BCa and outline their pros and cons. In so doing, a 
literature search for the past four years (January 2014 to February 2018) was performed on 
Pubmed, PMC, and Google scholar, using such words as “bladder cancer and bladder tumor 
detection, diagnosis and imaging”. A total of 81 published papers were found and are 
included in this review. The approaches described herein to image suspicious BCa are given 
in Table 1 and are summarized below.
Cystoscopy
Cystoscopy is performed in seven following different ways.
a) White Light Cystoscopy—White light cystoscopy (WLC), a widely available 
technique, that allows visualization of the mucosa within the bladder, is considered a gold 
standard method for detecting BCa [8]. There are two forms of WLC, rigid and flexible 
cystoscopy (FC). Rigid cystoscopy provides better image quality, enables working with a 
large lumen, and provides improved flow. FC on the other hand allows alternative patient 
positioning, easy passage, and enables examination of all parts of the bladder [8]. Therefore, 
FC is usually applied for initial assessment of patients. However, FC may miss up to 10% of 
papillary tumors. Furthermore its small working channel lumen does not allow resection of 
BCa [9]. Although technology has improved the WLC image quality significantly, WLC 
cannot reliably determine flat and carcinoma in situ (CIS) lesions, and cannot distinguish 
benign lesions from malignant masses. Such a distingtion is particularly important when 
Transurethral Resection of Bladder (TURB) is to be performed [9–11]. However, cystoscopy 
is recommended by national comprehensive cancer network (NCNN) and American 
urological association (AUA) guidelines for imaging patients with macroscopic hematuria 
[5, 12].
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Other novel endoscopic visualization techniques briefly described below have been 
developed to overcome some limitations of WLC. Although these methods are helpful for 
assessment of BCa, they are invasive, time-consuming, and expensive to perform. [9, 13].
b) Computer-Assisted Cystoscopy—For computer-assisted cystoscopy, standard 
cystoscopy images are assessed with color segmentation system. This system provided 
100% accurate detection of cancerous tissue. However false positive (FP) rate is 50% [11]. 
Therefore, this method is not commonly used.
c) Photodynamic Diagnosis—Photodynamic diagnosis (PDD), in which intravesical 
photosensitizing agents are introduced into the bladder to accumulate into the tumor cells, 
provides a helpful evaluation of BCa in the course of TURB. PDD has a higher sensitivity 
than WLC for detecting CIS and BCa. PDD-guided TURB has a lower recurrence rate than 
WLC-guided TURB [14]. However, the effect of PDD on progression-free survival is 
uncertain [9, 13].
d) Narrow Band Imaging—Narrow band imaging (NBI) used for increasing the contrast 
between the BCa and normal mucosa, enables imaging of mucosal vascular structures [9]. 
NBI can be helpful to determine whether TURB is required. However, whether its use is 
associated with a lower recurrence rate remains to be verified [13, 15].
e) Confocal Laser Endomicroscopy—Used for diagnosis and staging of BCa, 
Confocal Laser Endomicroscopy (CLE) uses fluorescein, administered intravenously or 
intravesically, and enables high-resolution cellular imaging. CLE is linked with improved 
surgery results. However, due to limited optical depth penetration, CLE cannot detect 
disease involving the muscularis propria [9, 16].
f) Optical Coherence Tomography—Optical coherence tomography (OCT) which uses 
infrared light, distinguishes between the layers of the bladder, and provides imaging of tissue 
and luminal surfaces with high spatial resolution. Urothelium appears in low intensity, 
lamina propria in slighgtly high intensity, but with low intensity for muscularis propria. OCT 
is useful for evaluation of non-muscle invasive BCa non-muscle invasive bladder carcinoma 
(NMIBC), CIS and recurrent tumor [9].
g) Storz Professional Image Enhancement System—Storz Professional Image 
Enhancement System (SPIES) employs a camera with four modes to enhance image quality 
in different clinical situations. The Clara mode enables homogeneous images; the Chroma 
mode improves the sharpness of the images; and the Spectra A and B modes provide better 
color contrast. Analysis of outcomes for SPIES-guided TURB remains a work in-progress 
[13].
Ultrasonography
There are two types of Ultrasonography techniques; a) Two-Dimensional Ultrasonography 
and b) Contrast Enhanced Ultrasonography.
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a) Two-Dimensional Ultrasonography—Two-Dimensional Ultrasonography (2D US) 
is a widely used and recommended method for evaluating hematuria and for staging, 
particularly in patients who have allergies to intravenous contrast agents and renal failure 
(Figure 1) [5, 17–21]. However, according to some publications 2D US is not recommended 
for the staging of BCa because it may not reveal the true local depth of its invasion [18–21]. 
Three-dimensional US provides BCa imaging in multiple planes, and may improve the 
accuracy of staging BCa [19]. A study evaluating the diagnostic accuracy of ultrasound T 
staging (UTS), in 152 elderly BCa patients, found that UTS results were comparable with 
those of histological T staging (HTS) [22]. In a 115 patient study, high conformity (75.7%) 
was found between the UTS and HTS, with 94.5% accuracy for stage T1. In other stages, the 
accuracy ranged between 84.9% and 91.8%. 2D US is helpful for differentiating the 
superficial BCa from muscle invasive BCa muscle invasive bladder carcinoma MIBC and 
can play an important role in planning treatment [22]. A comparative study between US and 
cystoscopy in 83 patients with low grade BCa, matched with propensity score was calculated 
from clinicopathological variable factors such as age, gender, tumor multiplicity, size, grade, 
and intravesical treatment. No significant difference in recurrence rate or in recurrent tumor 
characteristics was noted [20].
b) Contrast Enhanced Ultrasonography—CEUS is a new technique that uses 
microbubbles as a ultrasonographic contrast agent to determine the grade and stage of BCa 
[18]. The use of CEUS was investigated to predict T stage and grade of BCa prior to 
endoscopic resection in 110 patients suspected of BCa. Results were compared with 
histology. CEUS had the T stage: Ta sensitivity of 75%; specificity of 95%, T1 sensitivity 
65%; specificity 85% and muscle invasion sensitivity 90% with the specificity of 92% [18]. 
CEUS differentiated high grade (n=110) and low grade (n=82) urothelial BCa with 86% 
sensitivity, 90% specificity, 88% accuracy, 92% positive predictive value (PPV), and 82% 
negative predictive value (NPV). For high grade and low grade BCa the sensitivity was 85%, 
specificity 89%, accuracy 88%, PPV 85%, andNPV was 89% [23]. Similar results were 
found in another study, in 105 patients (55 low grade and 50 high grade). Time-intensity 
curve parameters for CEUS showed that the tumor microvessel density can be useful for 
assessing tumor angiogenesis [24]. Even though, new US methods have been developed, the 
role of US for staging BCa is not yet clearly defined [19].
Computed Tomography
CT scan is used in two different modes. The first, computed tomographic urography (CTU) 
can be performed with or without intravenous contrast agent, applied with sufficient phase to 
exclude a renal tumor and an excretory phase to assess upper urinary tract. CTU provides 
imaging of urinary system (the kidneys, ureters, bladder, and urethra) and is especially 
useful for urinary system pathologies. The second mode of CT scan is the conventional CT; 
this provides examinations of upper-lower abdomen and pelvis. CT is commonly used and is 
recommended method for staging BCa (Figure 2) [5, 17, 21, 25, 26].
a) Computed Tomographic Urography—In a study of 687 patients, 710 CTU were 
evaluated to detect BCa. CTU had 91.5% (650/710) accuracy, 86.3% (82/95) sensitivity, 
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92.4% (568/615) specificity and 63.6% (82/129) PPV. Some false positive results (n=47) 
were reported due to misinterpretation of images [27].
CTU with enhancement-triggered scan had highest sensitivity and NPV in corticomedullary 
phase (CMP). Therefore, CMP is recommended for bladder evaluation in patients with gross 
hematuria [28, 29]. CTU with enhancement-triggered scan and FC were compared in 435 
patients to detect BCa. Both methods detected BCa in 48 patients. CTU had 87% sensitivity, 
99% specificity, 91% PPV, and 98% NPV, while FC had 87% sensitivity, 10% specificity, 
98% PPV, and 98% NPV [30].
Diagnostic performance of CTU was compared with cystoscopy in 177 patients. CTU 
performed better with 96.3% sensitivity, 86.4% specificity, 92.8% diagnostic accuracy, 
92.9% PPV, and 92.7% NPV. The arterial acquisition phase diagnosed the lesions with the 
highest accuracy, and demonstrated 93.4% of all lesions [31].
b) Computed Tomography—CT of 231 BCa patients, following radical cystectomy 
(RC) and pelvic lymphadenectomy, had 93.6% specificity and 52.6% sensitivity. For local 
staging, the accuracy was 78%. Overstaging was low (6%) [32].
In a study of 206 patients with invasive BCa, increased bladder wall thickness, lymph node 
(LN) > 5mm in size, and associated with high risk of death, were imaged by CT. Results 
were helpful for prognostic information and MIBC management [25].
CT is faster and more cost-effective than MRI, but it is associated with the risk of ionizing 
radiation, high interobserver variability, and can neither differentiate bladder wall muscle 
layers, nor can it reliably distinguish T1 from T2 disease. Furthermore, its specificity and 
sensitivity are low for extravesical extension of early stage BCa and small metastatic lesions 
of BCa.[17, 21, 25, 26, 32–34].
Dual energy spectral CT is a relatively new method that provides multiparameteric imaging 
of the urinary system. On the monochromatic images, a threshold value of 73.4 Hounsfield 
unit demonstrated high sensitivity (77.0%) and specificity (82.5%) for differentiating 
posterior wall BCa from benign prostate hypertrophy [35].
Magnetic Resonance Imaging
MRI is used for preoperative staging and nodal imaging (Figure 3) of BCa for management 
of T2 or more advanced disease. MR Urography (MRU) which can be performed without 
use of contrast agent, is a suitable method for imaging patients with renal failure or those 
with allergies for iodinated contrast agent. Advanced MRI protocols described below 
provide functional information and can improve the efficacy for imaging BCa [5, 34, 36].
a) Morphologic MRI—MRI, unlike CT does not use ionizing radiation, offers superior 
soft tissue contrast, and provides more anatomical and functional information [19]. MRI also 
differentiates MIBC from NMIBC, and visualizes extramural invasion, T3b and T4 disease 
[36].
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Bladder distension level during MRI affects interpretation of the images [34]. T1-weighted 
(T1W)-MRI visualizes perivesical fat tissue infiltration, pelvic lymphadenopathy and bone 
metastasis. The detrusor muscle and BCa present similar signal intensity, and compromises 
the differentiation of bladder wall invasion on T1W-MRI without contrast. T2-weighted 
(T2W) MRI is superior to T1W-MRI for differentiation of NMIBC from MIBC. 
Furthermore, T2W-MRI can distinguish urine from the intraluminal BCa [19, 34]. 3Tesla 
(3T) MRI is better than 1.5Tesla (1.5T) MRI with regard to resolution, differentiation of 
tumor from normal tissues, and determination of the depth of tumor invasion [33]. MRI 
however cannot provide detailed tissue characterization and can overestimate the degree of 
bladder wall invasion after TURB or chemo-radiotherapy [34].
Split-bolus CTU, MR urography (MRU), and FC were compared in 150 patients for 
diagnosis of BCa which were verified with histopathology. CTU detected tumors with 
61.5% sensitivity, 94.9% specificity, 53.3% PPV, and 96.3% NPV, while MRU detected 
tumors with 79.9% sensitivity and 93.4% specificity, 52.6% PPV and NPV 97.1%. The 
number of bladder lesions detected using FC were 32, MRU 19, and CTU 15. Split-bolus 
CTU or MRU cannot replace cystoscopy in patients with hematuria [37].
A review of 24 publications for diagnostic performance for local staging of MIBC with 
pathologic confirmation showed that 3T-MRI had higher specificity (93%) than those using 
1.5T-MRI (83%). Studies using multiparametric MRI (conventional+≥2 functional 
sequences) showed the highest accuracy with sensitivity of 94% and specificity of 95% [38].
b) Diffusion-weighted (DW) MRI—DW-MRI is driven by the Brownian motion of water 
molecules that changes the apparent diffusion coefficient (ADC) value between normal 
tissue and tumor [19, 34, 39, 40]. The ADC value correlates with cell cycle and proliferative 
biomarkers [41, 42].
DW-MRI and Dynamic contrast-enhanced (DCE)-MRI at 3T were investigated for 
aggressiveness of BCa in 59 patients. The combination of ADC and wash-out rate 
determined the BCa aggressiveness with 96.7% sensitivity, 94.9% specificity, and 95.7% 
accuracy [43]. Also, ADC was useful for determining the recurrence and progression risk of 
BCa [19, 40, 44–46]. DWI-MRI however, helps distinguish benign and malignant bladder 
lesions, for staging, and for the assessment of efficacy of chemo-radiotherapy treatment [36]. 
DW-MRI does not require contrast agent, therefore DW-MRI can be used in patients with 
renal failure or allergies to contrast agents [39].
Qualitative and quantitative imaging characteristics of MRI and DWI-MRI were compared 
for detecting pelvic LNs in 36 BCa patients prior to cystectomy. Results were correlated 
with histopathology. The short axis (>5mm) LN imaging had 88% sensitivity and 75% 
specificity, the long axis (>6mm) LN imaging had 88% sensitivity and 71% specificity. ADC 
(< 1.35 mm and normalized to muscle) had 75% sensitivity and 68% specificity, and, in the 
absence of fatty hilum, the sensitivity and specificity were 75% and 71% respectively [40].
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Normalized ADC (nADC) of tumor, which was calculated by ADC(tumor)/ADC (reference 
tissue) using urine in the bladder and from muscles as a reference, was superior to ADC for 
estimating grade of BCa [47].
The accuracy of differentiating muscle invasion and perivesical fat invasion were found 
higher with DW-MRI and MRI combined, than MRI alone, for T staging in 160 patients 
[48]. Correlative values between ADC and clinicopathological parameters, such as tumor 
diameter, grade, and T stage, were also examined. DWI-MRI provided a better tissue 
contrast than T1-MRI and T2-MRI.
3TDW-MRI was superior to T2W-MRI for deleneating the T stage, for differentiating T1 
tumor from T2 or more severe disease, and for showing stalks of BCa [49].
DW-MRI diagnosed BCa with 95% sensitivity and 85% specificity and differentiated MIBC 
from NMIBC with 85% sensitivity and 90% specificity [50].
For differentiating residual BCa from postoperative changes before a second TURB, in 75 
patients, T2W-MRI had 100% sensitivity, only 18% specificity, and 53% accuracy. DCE-
MRI had 100% sensitivity, 12% specificity, 50% accuracy and DW-MRI had 92% 
sensitivity, 82% specificity, 87% accuracy [51].
The use of DW-MRI was investigated for differentiating recurrent tumor from chronic 
inflammation and fibrosis after surgery. For detecting recurrent tumors the accuracy, 
sensitivity, specificity, and PPV of DW-MRI were 92.6%, 100%, 81.8%, and 88.9%, 
respectively which were higher than those of DCE-MRI (59.3%, 81.3%, 27.3%, and 54.2%, 
respectively). The nADC of recurrent tumors were significantly lower than those of 
postoperative inflammation or fibrosis [52].
Furthermore, DW-MRI vizualised small LN metastases in normal-sized LNs that 
conventional imaging modalities would have missed [53]. ADC is a promising parameter for 
estimation of BCa stage and grade with high sensitivity and specificity [54]. However, DW-
MRI has several disadvantages, including low tumor specificity and poor spatial resolution 
[55].
c) Dynamic contrast-enhanced MRI—Dynamic contrast-enhanced MRI (DCE-MRI), 
which uses paramagnetic contrast agents, is helpful for depicting tumor vascularity, 
ischemia-necrosis and mass in the bladder lumen on delayed-phase images. DCE-MRI 
utilizes T1W sequences providing high-resolution images for detection of BCa. DCE-MRI is 
helpful for predicting recurrence and chemotherapeutic response [34, 56]. DCE-MRI has 
strong interobserver agreement and provides high accuracy for distinguishing MIBC from 
NMIBC [33].
Compared with conventional T2W-MRI alone, the addition of multitransmit 3T-DCE-MRI 
significantly improved interobserver agreement, and the characterization of BCa especially 
small malignant tumors and tumors within areas of bladder wall thickening. 3T-DCE-MRI 
mapping is a promising method to augment BCa imaging beyond the limitations of 
cystoscopy and CT [33].
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The performance of DCE-MRI was evaluated for histological response after chemotherapy 
on localized urothelial BCa in 12 patients. DCE-MRI was performed prior to chemotherapy 
to measure the size, thickness, relative enhancement at the arterial and venous phases of 
each tumor. DCR-MRI helpfully increased selection of patients for localized BCa surgery 
[57].
d) Lymphotropic Nanoparticle Enhanced MRI—Lymphotropic Nanoparticle 
Enhanced MRI (LNMRI) uses ultrasmall paramagnetic iron oxide particles. When 
administered intravenously, they reach LNs through the lymphatics and differentiate benign 
and malignant LNs. Additional clinical studies are required to determine the role of this 
method for BCa [58].
e) Multiparametric MRI—Multiparametric MRI (mpMRI) is composed of T1W-MRI, 
T2W-MRI and functional MRI methods, including DCE-MRI and DW-MRI. mpMRI 
combines anatomic and functional MRI sequences and plays a role for detection, staging, 
and local recurrence of BCa [58]. In a recent study, efficacy of mpMRI for staging of BCa 
after TURB in 45 patients was examined. mpMRI was found both sensitive (92%) and 
specific (84%) method for MIBC detection. The investigators conluded that, mpMRI may be 
helpful for local staging of BCa after TURB[59]. However, to assess its efficacy carefully, 
clinical studies in large patient groups are required.
PET/CT
18F-FDG PET/CT—For nodal metastasis in BCa sensitivity of CT is low. CT may fail to 
detect nearly 40% of LN metastases [60]. PET/CT is used in oncology for staging, restaging, 
examining early recurrence, and assessing prognosis. 18Fluorine-2-deoxy-2-
fluorodeoxyglucose (18F-FDG), the most commonly used agent in PET/CT imaging, [61] is 
excreted through the kidneys. Therefore, differentiation of bladder pathology or LN’s from 
physiological 18F-FDG activity is difficult (Figure 4). Forced diuresis may be used to reduce 
physiological 18F-FDG uptake in the bladder [60, 61].
The sensitivity of 18F-FDG-PET/CT was 56% and the specificity was 98% for nodal 
metastases as confirmed by histology in 78 patients with BCa scheduled for RC (radical 
cystectomy). PET/CT was more accurate than CT alone for staging BCa [60].
For initial staging after transurethral biopsy (n=34), PET/CT sensitivity was 87.5%, 
specificity was 80%, and accuracy was 82%. For CT sensitivity was 66%, specificity 57%, 
and accuracy was 60%. For restaging BCa (n=43), PET/CT had 85% sensitivity, 60% 
specificity, and 70% accuracy. CT, for staging, had 80% sensitivity, 50% specificity, and 
58% accuracy. The maximum standardized uptake value (SUVmax) for primary tumor, 
ranged from 5.7–30.4 and for LN metastases ranged from 3.5–13.8. Both PET/CT and CT 
primary tumor detection was 88% and were confirmed by histopathology [62].
18F-FDG-PET/CT and CT with histopathological examination of LNs were compared in 54 
locally advanced BCa. PET/CT had 86% specificity, 58 % PPV, and 76% NPV, while CT 
alone had 89% specificity, 64 % PPV, and 77 % NPV. Both methods had 41% sensitivity for 
LN metastasis [63].
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Role of 18F-FDG-PET/CT as an indicator of response to chemotherapy was investigated in 
patients with oligometastatic BCa. PET/CT was performed before and after chemotherapy, 
and results were confirmed with histology. PET/CT predicted histological nodal 
chemotherapy response in 37 of 43 patients (86%) with LN metastasis following 
lymphadenectomy. For response, FDG-PET/CT had 100% sensitivity, (37 out of 37), 17% 
specificity, (1 out of 6), 88% PPV (37 out of 42), and 100% NPV. (1 out of 1) [64].
Preoperative 18F-FDG-PET/CT imaging demonstrated more malignant findings than CT in 
47% of high risk MIBC patients. PET/CT also changed the therapy plan for 27% patients 
[65].
Extravesical 18F-FDG avid lesions, suspicious for malignancy on PET/CT, were correlated 
with mortality in 211 patients with MIBC. Data suggested that 18F-FDG may be an 
independent prognostic indicator of mortality [66].
SUVmax of early dynamic imaging with 18F-FDG was independent of the SUVmax of 
delayed images. High-grade tumors demonstrated higher SUVmax than low-grade tumors in 
the early dynamic imaging in pT1 tumors. Non-invasive pTa tumors had significantly lower 
SUVmax than higher stage tumors during early dynamic imaging [67].
18F-FDG-PET/CT was compared with CT for LN staging in high-grade T1 tumor [n=9] or 
MIBC [n=52]. On a patient-based analysis, PET/CT had 47.1% sensitivity, 93.2% 
specificity, 72.7% PPV, 82.0% NPV, whereas CT had 29.4% sensitivity, 97.7% specificity, 
78.2% PPV, 78.2% NPV. PET/CT had low sensitivity for LN staging of MIBC and it did not 
increase diagnostic accuracy of CT for LN metastasis. This can be affected by various 
factors, such as patient population, extent of LN dissection, and cut off value of SUV [68].
PET/CT was compared with CT to investigate pelvic LN and distant metastasis in patients 
with MIBC or high-risk NMIBC. Results were compared with histology. For detecting 
distant metastasis (n=207), sensitivity of PET and CT was 54%, 41%, respectively. Both 
scans had similar specificities of 97% and 98%. For pelvic LN involvement (n=93), the CT 
scan had 46% sensitivity and 98% specificity and PET/CT scan had 68% sensitivity and 
95% specificity. Therefore, dual imaging should be performed but only in selected patients 
[69].
Carbon(C)-11-Choline PET/CT—11C-choline-PET/CT is used for staging of BCa. The 
main advantage of 11C-choline is its low urinary excretion. Its sensitivity is higher than 18F-
FDG for showing local relapse of BCa [70].
For relapse of BCa, 11C-choline-PET/CT had 66.7% sensitivity, 84.6% specificity, 76% 
accuracy, 80% PPV, and 73.3% NPV. For imaging LNs and distant relapse, this method had 
90% sensitivity, 93.3% specificity, 92% accuracy, 90% PPV, and 93.3% NPV. No FP or FN 
were detected [70].
Tabulating overall survival (OS) and cumulative incidence of cancer-specific death (CSD), 
the prognostic value of 11C-choline-PET/CT was compared with CT and with histology for 
preoperative staging in 44 BCa patients. The imaging results were in concordance with OS 
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and cumulative incidence of CSD. No statistically significant difference was found in OS 
and CSD between the patient groups for organ-limited versus non-organ-limited disease or 
LN involvement. 11C-choline PET/CT may play a role to predict prognosis [71].
The role of 11C-choline-PET/CT with Contrast Enhanced Computed Tomography (CECT) 
was compared for preoperative LN staging in 26 BCa patients and results were confirmed 
with pathology. On a patient-based analysis, PET/CT had 42% sensitivity and 84% 
specificity while CECT had 14% sensitivity and 89% specificity. On a region-based analysis, 
PET/CT had 11% sensitivity and 82% specificity while CECT had 5% sensitivity and 80% 
specificity. On a lesion-based analysis, PET/CT had 10% sensitivity and 64% specificity and 
CECT had sensitivity 2% and specificity 63% [72].
11C-choline-PET/CT was compared with histology for preoperative LN evaluation in 59 
BCa patients. On a regional-based analysis, PET/CT was positive for primary cancer and/or 
local relapse in bladder bed in 54.2% of the patients. Pathological LN uptake was found in 
23.7% of the patients. For LN metastasis detection, PET/CT had 59% sensitivity, 90% 
specificity, 71% PPV, 84% NPV and 81% accuracy [73]. A longer lived 18F-choline has not 
yet been deeply investigated for imaging BCa.
PET/MRI
A relatively recent modality, PET/MRI provides advantages of the high resolution of MRI 
and metabolic information of PET. PET/MRI differentiates normal and pathologic structures 
more clearly than PET/CT and facilitates coregistration of the bladder wall, bladder 
pathologies and pelvic LNs. Therefore PET/MRI is considered to be helpful for the 
management of BCa [74–76].
Diagnostic performance of MRI and 18F-FDG-PET/MRI using a diuresis protocol was 
compared in 22 BCa patients. At a score of 3, PET/MRI provided higher accuracy for 
detection of BCa (86% vs. 77%), pelvic LNs (95% vs. 76%), and nonnodal pelvic 
malignancy (100% vs. 91%). Additional PET was useful for showing exact level of 
suspicious nodal/nonnodal findings in the pelvis which were equivocal on MRI alone [74].
A PET/MRI study noted improved bladder wall coregistration and slightly increased 
detection of bladder masses and pelvic LNs [77].
18F-FDG-PET/MRI was investigated for local or metastatic staging of 11 BCa patients. With 
T1W and T2W images of the pelvis, MRI was helpful for staging, concluding that PET/MRI 
increased diagnostic utility of PET for the management of MIBC [78].
18F- Sodium Fluoride PET/CT and bone scintigraphy
18F-Sodium Fluoride (NaF) is a positron emitting radiopharmaceutical used for PET/CT 
imaging of bone. 18F-NaF-PET/CT has higher sensitivity and better image quality than bone 
scintigraphy, making it superior for the detection of osseous metastasis of BCa [79, 80]. 
Bone scintigraphy is recommended for MIBC patients with suspicious bone metastasis [5]. 
Preoperative bone imaging is associated with improved survival of MIBC, better patient 
selection for surgery [81].
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Conclusion
Great strides have been made for imaging BCa. Nonetheless, current methods suffer from 
inaccurate detection of BCa and metastatic lesions. Cystoscopy is recommended for patients 
with painless hematuria. However, cystoscopy can not accurately show CIS and has 
difficulty differentiating benign masses from malignant lesions, especially before TURB. 
Novel cystoscopy techniques are promising for imaging BCa, but further clinical evaluation 
is needed. US is performed for symptomatic patients to exclude urinary system pathologies. 
CT is preferred for staging, but cannot differentiate T1 and T2 BCa. MRI can differentiate 
MIBC from NMIBC and has improved efficacy for local staging. However, MRI is not 
suitable for patients who have prosthesis or renal failure and is more time consuming than 
CT. These results are summarized in Table 2. Both CT and MRI have low sensitivity for 
nodal staging where PET/CT plays a leading role. PET/CT is also important for restaging 
and assessing treatment response. For PET/CT, 11C-Choline may be an agent of choice since 
it has low urinary excretion, and higher sensitivity for depicting local relapse. However, the 
half-life of 11C-choline is short, and requires an in house cyclotron to produce it. These 
results are summarized in Table 3. 18F-NaF is useful for assessment of blastic bone 
metastasis. Bone scintigraphy is recommended before TURB. PET/MRI provides better 
differentiation of normal and pathologic structures as compared with PET/CT. PET/MRI is a 
relatively novel modality to image BCa. However further studies are needed to evaluate its 
full potential.
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Glossary of abbreviations
ADC Apparent Diffusion Coefficient
AUA American Urological Association
BCa Bladder Cancer
11C 11Carbon
CEUS Contrast Enhanced Ultrasonography
CECT Contrast Enhanced Computed Tomography
CIS Carcinoma in situ
CLE Confocal Laser Endomicroscopy
CMP Corticomedullary phase
CSD Cumulative incidence of cancer-specific death
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CT Computed Tomography
CTU Computed Tomographic Urography
2D US Two-dimensional Ultrasonography
DCE-MRI Dynamic Contrast Enhanced Magnetic Resonance Imaging
DW-MRI Diffusion-Weighted Magnetic Resonance Imaging
FC Flexible Cystoscopy
18F-FDG 18Fluorine-2-deoxy-2-fluorodeoxyglucose
FP False positive
HTS Histological T staging
LN Lymph node
LNMRI Lymphotropic Nanoparticle Enhanced MRI
mpMRI Multiparametric MRI
MRI Magnetic Resonance Imaging
MRU Magnetic Resonance Urography
nADC Normalized ADC
NaF Sodium Fluoride
NBI Narrow Band Imaging
NCNN National Comprehensive Cancer Network
NMIBC Non-Muscle Invasive Bladder Cancer
MIBC Muscle Invasive Bladder Cancer
NPV Negative Predictive Value
OCT Optical Coherence Tomography
OS Overall survival
RC Radical Cystectomy
PDD Photodynamic Diagnosis
PET/CT Positron Emission Tomography/Computed Tomography
PET/MRI Positron Emission Tomography/Magnetic Resonance Imaging
PPV Positive Predictive Value
SPIES Storz Professional Image Enhancement System
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SUVmax Maximum Standardized Uptake Value
1.5T 1.5 Tesla
3T 3 Tesla
TURB Transurethral Resection of Bladder
T1W-MRI T1-weighted Magnetic Resonance Imaging
T2W-MRI T2-weighted Magnetic Resonance Imaging
UTS Ultrasound T staging
US Ultrasonography
WLC White Light Cystoscopy
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Fig. 1. 
Sagittal ultrasonography image of the urinary bladder, demonstrating a lobulated mucosal 
mass with calcifications (arrow), representing transitional cell carcinoma of the bladder.
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Fig. 2. 
Transaxial CT image through the bladder obtained at an 8 minute delay following 
intravenous contrast administration. The irregular round filling defect in the right posterior 
aspect of the bladder (arrow) represents a transitional cell carcinoma. There is thickening of 
the adjacent bladder wall, but not definite spread beyond the bladder.
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Fig. 3. 
Contrast enhanced T1 weighted axial MRI image of the pelvis demonstrates an irregular 
enhancing mass filling the bladder. The margin of the mass is inseparable from the bladder 
wall. Irregular enhancement along the bladder wall (arrow) suggests transmural spread of 
disease.
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Fig. 4. 
78-year-old man with large papillary tumor on left lateral wall and high grade, nonpapillary 
tumor involving the left trigone just lateral to left UO and posterior left bladder neck on 
cystourethroscopy.
Due to concentration of 18F-FDG in the urinary bladder, any increased activity of the 
thickened bladder wall (arrow) cannot be determined on the PET/CT image of the pelvis 
(A). Asymmetric thickening of the left urinary bladder wall (arrow), on the pelvis CT part of 
PET/CT imaging (B) and it likely corresponds to known bladder malignancy. Along the left 
pelvic sidewall there is a 2.4 × 1.3 cm hypermetabolic lymph node with a maximum SUV of 
6.17 (C).
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Table 1
Initial evaluation of suspicious bladder cancer and Recommendations
Modality Patient condition, status and Recommendations Reference
Cystoscopy • microscopic hematuria (in >35 years old): recommended
• macroscopic hematuria (all patients): recommended
• bladder cancer risk factors (all patients): performed
• microscopic hematuria (<35 years old): can be performed according to bladder cancer suspicion
[5,12]
CTU • Asymptomatic microscopic hematuria: CTU (with and without intravenous contrast agent) is 
applied with sufficient phases to exclude a renal tumor and an excretory phase to assess upper 
urinary tract.
[5,12]
MRU • Recommended for patients with allergies to intravenous contrast agents and renal failure [5,12]
CT • Recommended before bladder tumor resection [5]
MRI • Recommended before bladder tumor resection
• Recommended for patients with allergies to intravenous contrast agents and renal failure
[5,12]
US • Recommended for patients with allergies to intravenous contrast agents and renal failure [5,17–21]
PET/CT • MIBC: staging, follow-up (patients who do not have basal imaging, in high risk patients in case of 
metastasis suspicion, guidance for biopsy, suspicion of bone metastasis)
[5,6]
Bone scan • MIBC ( suspicion of bone metastasis) [5]
Note– CT= Computed Tomography, MRI= Magnetic Resonance Imaging, CTU= Computed Tomography Urography, MRU= Magnetic Resonance 
Urography, US= Ultrasonography, PET/CT= Positron Emission Tomography/Computed Tomography, MIBC= Muscle Invasive Bladder Cancer
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